Moreover, the addition of chemotherapy or gemcitabine, to this combination of a vaccine and a GITR monoclonal antibody, reduces the tumor‐suppressive environment and induces a persistent memory immune response [22]. This evidence concerns the gene TNFRSF18 and neoplasm.